Drug name: PRIMA-1 + p53 peptide-based vaccines


Related CSCTT Targets

ALDH-high cells [ref.1]

PRIMA-1

Cas.no PubChem ID
5608-24-2 322968
Known Target
Cellular tumor antigen p53P04637
Structure
...
Introduction
PRIMA-1, a novel low molecular weight compound, rescues the tumor-suppressing function of mutant p53 proteins and shows anti-tumor activity in vivo. P53 severs as a crucial tumor suppressor and mutant p53 is expressed at high levels in many tumors. PRIMA-1 is considered as a lead compound for the development of anticancer drugs targeting mutant p53.

p53 peptide-based vaccines

Cas.no PubChem ID
Known Target
Cellular tumor antigen p53P04637
Structure
...
Introduction
Peptide vaccines prime an antigen-specific immune response through their interactions with antigen-presenting cells (APCs) and subsequently cytotoxic T lymphocytes (CTLs), which ultimately kill antigen-expressing leukemia targets. These interactions, which require functional APCs that can provide adequate costimulation to T cells, in addition to antigen presentation, are complex and are the subject of a large body of investigations.

Reference

  • [1] Targeting cancer stem cells with p53 modulators.
    Zhang, Z., L. Liu, R. Gomez-Casal, X. Wang, R. Hayashi, E. Appella, L. Kopelovich and A. B. DeLeo (2016). Oncotarget.. [ 27074569 ]

Back to top